Optimizing Reperfusion to Improve Outcomes and Neurologic Function

Last updated:
2026-07-25
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

OPTIMIZING REPERFUSION TO IMPROVE OUTCOMES AND NEUROLOGIC FUNCTION (ORION): A MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED, PARALLEL-GROUP, PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF JX10 IN ACUTE ISCHEMIC STROKE WITH LATE PRESENTATIONS

Intervention/treatment:
JX10
Medical condition:
ACUTE ISCHEMIC STROKE
Protocol code:
JX10002
Control number:
293902
Status:
Recruiting
Approved:
January 24, 2025
Trial phase:
Phase 2, Phase 3
For more information:
ClinicalTrials.gov - NCT06990867
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 90 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Corxel Pharmaceuticals Study Information Center
Role
CONTACT
Phone:
201-268-3723
Sponsor
CORXEL PHARMACEUTICALS, CO, LTD

Locations

Corxel Investigational Site
Edmonton
RECRUITING
Name
Study Director
Role
CONTACT
Phone:
201-268-3723
Corxel Investigational Site
Kingston
RECRUITING
Name
Study Director
Role
CONTACT
Phone:
201-268-3723
Did you find what you were looking for?